| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 83611 |
DOTA-PSMA-617 1,4,7,10-四氮杂环十五烷偶联PSMA-617 |
133 |
h |
2024-12-18 |
| 83612 |
DOTA-VAP-1 螯合剂DOTA偶联VAP-1靶向肽 |
274 |
h |
2024-12-18 |
| 83613 |
DOTA-GIP-C803 DOTA螯合剂缀合GIPC803肽 |
116 |
h |
2024-12-18 |
| 83614 |
DOTA-mPS 螯合剂DOTA修饰微米级聚苯乙烯 |
133 |
h |
2024-12-18 |
| 83615 |
DOTA-HBED-bisphosphonate DOTA-HBED-二膦酸盐 |
141 |
h |
2024-12-18 |
| 83616 |
CAS号：2226472-28-0 ，DBCO-PEG4-Val-Cit-PAB-PNP |
152 |
WYQ |
2024-12-18 |
| 83617 |
cas:2112738-09-5， Mal-PEG4-Val-Cit-PAB-PNP |
159 |
WYQ |
2024-12-18 |
| 83618 |
Mal-PEG8-Val-Cit-PAB-PNP，可以溶解于DCM、DMF、DMSO、THF等有机溶剂，以及水中。 |
197 |
WYQ |
2024-12-18 |
| 83619 |
Mal-PEG2-Val-Ala-PAB-PNP，含有马来酰亚胺（Mal）官能团、两个单元的聚乙二醇（PEG2）间隔物、缬氨酸（Val）和丙氨酸（Ala）的序列 |
124 |
WYQ |
2024-12-18 |
| 83620 |
Mal-PEG2-Val-Cit-PABA（CAS号：1662687-83-3） |
150 |
WYQ |
2024-12-18 |
| 83621 |
CAS号：1096584-62-1， Mal-Val-Cit-PAB-PNP |
116 |
WYQ |
2024-12-18 |
| 83622 |
Mal-amido-PEG2-Val-Cit-PAB-OH，马来酰亚胺-酰胺-二聚乙二醇-缬氨酸-瓜氨酸-PAB-羟基 |
111 |
WYQ |
2024-12-18 |
| 83623 |
CAS号：1949793-41-2 ，Mal-amido-PEG4-Val-Cit-PAB-OH |
117 |
WYQ |
2024-12-18 |
| 83624 |
DOTA-伊班膦酸 DOTA-IBA |
167 |
h |
2024-12-18 |
| 83625 |
FA-DOTA-PEG-PLGA 叶酸-DOTA-聚乙二醇-聚乳酸-羟基乙酸共聚物 |
127 |
h |
2024-12-18 |
| 83626 |
DOTA-泛素29-41 |
115 |
h |
2024-12-18 |
| 83627 |
cas:1226403-39-9，N-(2-(3,4-Difluorophenoxy)ethyl)-4-formylbenzamide |
124 |
kx |
2024-12-18 |
| 83628 |
Cu-64 DOTA-曲妥珠单抗 Cu-64-Herceptin |
223 |
h |
2024-12-18 |
| 83629 |
CAS号：2112738-13-1 ，Mal-amido-PEG2-Val-Cit-PAB-PNP |
149 |
WYQ |
2024-12-18 |
| 83630 |
CAS号：2055041-40-0 ， Azido-PEG1-Val-Cit-PAB-OH |
127 |
WYQ |
2024-12-18 |
| 83631 |
cas:1226006-55-8，N-(2-(3-Ethoxyphenoxy)ethyl)-4-formylbenzamide， ADC试剂 |
102 |
kx |
2024-12-18 |
| 83632 |
DOTA-LTVSPWY 双功能螯合剂DOTA偶联肽LTVSPWY |
142 |
h |
2024-12-18 |
| 83633 |
CAS号：2055024-65-0 ，Azido-PEG3-Val-Cit-PAB-OH |
128 |
WYQ |
2024-12-18 |
| 83634 |
DOTA-CCK-66 大环DOTA偶联CCK2R靶向化合物CCK-66 |
412 |
h |
2024-12-18 |
| 83635 |
cas:1228153-04-5，4-Formyl-N-(2-(naphthalen-2-yloxy)ethyl)benzamide |
145 |
kx |
2024-12-18 |
| 83636 |
抗DOTA IgG-scFv BsAb anti-DOTA IgG-scFv BsAb |
198 |
h |
2024-12-18 |
| 83637 |
cas:1226217-30-6，4-Formyl-N-(2-(4-isopropylphenoxy)ethyl)benzamide |
148 |
kx |
2024-12-18 |
| 83638 |
DOTA-rL-A9肽 DOTA偶联核定位序列(NLS)-移植的her 2-受体亲和肽 |
170 |
h |
2024-12-18 |
| 83639 |
cas:796073-59-1，2,5-Dioxopyrrolidin-1-yl 4-(methyldisulfanyl)pentanoate |
107 |
kx |
2024-12-18 |
| 83640 |
DOTA-E[c(RGDFK)]2 双功能螯合剂偶联的RGD多肽E[c(RGDfK)]2 |
113 |
h |
2024-12-18 |
| 83641 |
DBCO-C4-Val-Cit-PABC-PNP，分子式：C46H49N7O10 |
123 |
WYQ |
2024-12-18 |
| 83642 |
DBCO-(PEG)3-VC-PAB-MMAE，CAS号：57103-68-1 |
90 |
WYQ |
2024-12-18 |
| 83643 |
cas:1134280-65-1，2,5-Dioxopyrrolidin-1-yl 3-((2,4-difluorobenzyl)oxy)propanoate |
110 |
kx |
2024-12-18 |
| 83644 |
DBCO-PEG3-acetic-Val-Cit-PAB（二苯并环辛炔） |
124 |
WYQ |
2024-12-18 |
| 83645 |
cas:1824718-79-7，SPDH， ADC试剂 |
118 |
kx |
2024-12-18 |
| 83646 |
cas:1232769-29-7，2,5-dioxopyrrolidin-1-yl 19-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-19-oxo-4,7,10,13,16-pentaoxanonadecan-1-oate |
119 |
kx |
2024-12-18 |
| 83647 |
Amino-PEG2-VG-N-Bis(PEG1-azide)，氨基-二聚乙二醇-VG-N-双（一聚乙二醇-叠氮） |
166 |
WYQ |
2024-12-18 |
| 83648 |
Alkyne-Val-Cit-PAB-FAM，炔-VAL-CIT-PAB-FAM |
110 |
WYQ |
2024-12-18 |
| 83649 |
cas:1226218-43-4，4-Formyl-N-(2-(2,3,6-trimethylphenoxy)ethyl)benzamide |
117 |
kx |
2024-12-18 |
| 83650 |
双功能螫合剂DOTA偶联MAG3 DOTA-MAG3 |
147 |
h |
2024-12-18 |
| 83651 |
Alkyne-Val-Cit-PAB-PNP，炔-Val-Cit-PAB-PNP |
121 |
WYQ |
2024-12-18 |
| 83652 |
DOTA-MSH2 金属螯合剂DOTA偶联二聚体肽(MSH2) |
132 |
h |
2024-12-18 |
| 83653 |
cas:796073-64-8，(S)-2,5-Dioxopyrrolidin-1-yl 4-(methyldisulfanyl)pentanoate |
109 |
kx |
2024-12-18 |
| 83654 |
N,N-二乙基正辛硫基乙酰胺,(N,N-Diethyl-α-(OctlyThio)-Acetamide)简称DOTA |
146 |
h |
2024-12-18 |
| 83655 |
cas:437655-95-3，Fmoc-NH-PEG4-CH2COOH， 5,8,11,14-四氧杂-2-氮杂十六碳二酸 1-芴甲基酯 |
125 |
kx |
2024-12-18 |
齐岳微信公众号
官方微信
库存查询